Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AKTX stock hub

Akari Therapeutics, Plc has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AKTXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

7.1M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AKTX

In the news

Latest news · AKTX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-68.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-27.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AKTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

173

Groups with data

Currency

USD

Showing 173 of 173 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001541157
Company name	Akari Therapeutics, Plc
Country	United States
Country code	US
Cusip	00972G405
Employees	6
Employees Change	-3%
Employees Change Percent	-33.33
Enterprise value	$2.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US00972G4055
Last refreshed	2026-05-10
Market cap	$7.1M
Market cap category	Nano-Cap
Price	$6.25
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	AKTX
Website	https://www.akaritx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-244.56%
FCF yield	-149.41%
P/B ratio	0.25x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-17.3M
Net Income Growth Years	1%
Profit Per Employee	$-2.9M
ROA	-15.36
Roa5y	-72.8
ROCE	-34.03
ROE	-68.43
Roe5y	-449.3
ROIC	-27.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-53.34%
Cagr1y	-88.8%
Cagr3y	-64.68%
Cagr5y	-66.35%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$47.9M
Cash	$5.2M
Current Assets	$5.5M
Current Liabilities	$12.4M
Debt	$754,000
Debt Equity	$0.03
Equity	$28.3M
Interest Coverage	-12.74
Liabilities	$19.6M
Long Term Assets	$42.4M
Long Term Liabilities	$7.2M
Net Cash	$4.4M
Net Cash By Market Cap	$62.9
Net Debt Equity	$-0.16
Tangible Book Value	$-14.1M
Tangible Book Value Per Share	$-12.46
WACC	16.64

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.44
Net Working Capital	$-11.3M
Quick ratio	0.42
Working Capital	$-6.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-181.85%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.95%
1Y total return	-88.78%
200-day SMA	19.81
3Y total return	-95.6%
50-day SMA	6.39
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.57%
All Time High	20,880
All Time High Change	-99.97%
All Time High Date	2015-09-28
All Time Low	3.25
All Time Low Change	92.31%
All Time Low Date	2026-04-06
ATR	0.7
Beta	0.65
Beta1y	2.06
Beta2y	1.08
Ch YTD	-45.93
High	6.58
High52	56.8
High52 Date	2025-06-02
High52ch	-89%
Low	6.13
Low52	3.25
Low52 Date	2026-04-06
Low52ch	92.31%
Ma50ch	-2.19%
Price vs 200-day SMA	-68.46%
RSI	55.34
RSI Monthly	30.69
RSI Weekly	31.09
Sharpe ratio	-1.52x
Sortino ratio	-1.99
Total Return	-181.85%
Tr YTD	-45.93
Tr1m	64.47%
Tr1w	14.26%
Tr3m	-33.51%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-2.8
Operating Income	$-12.1M
Price target	$33.5
Price Target Change	$436

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	435,628%
Float Percent	38.49%
Net Borrowing	1,047,000
Shares Insiders	54.61%
Shares Institutions	3.37%
Shares Out	1,131,710
Shares Qo Q	32.27%
Shares Yo Y	181.85%
Short Ratio	0.48
Short Shares	4.66

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-13.5M
Average Volume	54,441.4x
Bv Per Share	25.03
Ch10y	-99.95
Ch1m	64.47
Ch1w	14.26
Ch1y	-88.78
Ch3m	-33.51
Ch3y	-95.6
Ch5y	-99.57
Ch6m	-75.53
Change	-5.02%
Change From Open	-4.43
Close	6.58
Days Gap	-0.61
Depreciation Amortization	14,000
Dollar Volume	26,746.1
Earnings Date	2026-05-14
Earnings Time	bmo
EBIT	$-12.1M
EBITDA	$-12.1M
EPS	$-20.55
F Score	2
FCF	$-10.6M
FCF EV Yield	-402.72x
FCF Per Share	$-9.34
Financing CF	13,171,000
Fiscal Year End	December
Goodwill	8,430,000
Income Tax	$-1M
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-30
Last Report Date	2025-12-31
Last Split Date	2026-03-31
Last Split Type	Reverse
Last10k Filing Date	2026-03-30
Ma150	14.14
Ma150ch	-55.79%
Ma20	5.58
Ma20ch	12.11%
Net CF	2,604,000
Next Earnings Date	2026-05-22
Open	6.54
Optionable	No
Position In Range	26.67
Post Close	6.25
Postmarket Change Percent	1.92
Postmarket Price	$6.37
Price Date	2026-05-08
Relative Volume	0.08x
Share Based Comp	2,890,000
Tr6m	-75.53%
Us State	Florida
Volume	4,279.4

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AKTX pay a dividend?

Capital-return profile for this ticker.

Performance

AKTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AKTX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+3.4%

Float: +38.5% of shares outstanding

Insider ownership

+54.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AKTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

55.3

Neutral momentum band

Price vs 200-day MA

-68.5%

50/200-day relationship not available

Beta (5Y)

0.65

Less volatile than the market

Sharpe ratio

-1.52

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AKTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AKTX stock rating?

Akari Therapeutics, Plc is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AKTX analysis?

The full report lives at /stocks/AKTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AKTX?

The latest report frames AKTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AKTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.